Nicolai Tangen meets Pfizer CEO Albert Bourla for a wide-ranging conversation on leadership, science, and the future of global healthcare. Bourla reflects on leading Pfizer through the COVID-19 vaccine breakthrough and how it transformed the company. The discussion also dives into Pfizer’s strategic shift toward innovative medicine, including major investments in oncology and obesity, and the high-stakes decisions behind multibillion-dollar acquisitions.
Looking ahead, the conversation explores how artificial intelligence is set to transform drug discovery, clinical trials, and the broader healthcare system. Bourla offers a candid view on global competition, particularly the rapid rise of China in biotech, and what it will take for companies like Pfizer to stay ahead. Beyond business, Bourla opens up about leadership, how to build resilience, foster organizational confidence, and continuously evolve as a CEO. He also shares a deeply personal story about his mother, a Holocaust survivor, and how her perspective shaped his optimism and drive.
In Good Company is hosted by Nicolai Tangen, CEO of Norges Bank Investment Management. New full episodes every Wednesday, and don't miss our Highlight episodes every Friday.
The production team for this episode includes Isabelle Karlsson and PLAN-B's Niklas Figenschau Johansen, Sebastian Langvik-Hansen and Pål Huuse. Background research was conducted by Isabelle Karlsson.